文献速递肝病

无启动子无核酸酶基因组编辑使甲基丙二酸血症小鼠的校正肝细胞获得生长优势

Promoterless, Nuclease-Free Genome Editing Confers a Growth Advantage for Corrected Hepatocytes in Mice With Methylmalonic Acidemia.
PubMed 文献 · Hepatology · 2021-05-21

研究设计无启动子整合型AAV载体,将甲基丙二酰辅酶A变位酶(MMUT)转基因插入白蛋白基因座3'端,并在甲基丙二酸血症(MMA)小鼠模型中进行测试。新生期递送后,编辑实现了肝脏永久性校正,伴甲基丙二酸和Fgf21水平降低及生存改善,且未发生肝细胞癌;随时间推移,转基因表达增加、甲基丙二酸进行性降低,白蛋白-MMUT整合及校正肝细胞数量增加,而野生型动物无此现象。MMA背景下MMUT表达赋予编辑细胞选择性生长优势,从而增强治疗反应。

要点

  • AAV介导的无启动子无核酸酶编辑将MMUT插入白蛋白基因座,在新生期治疗的MMA小鼠中实现永久肝脏校正。
  • 治疗伴随甲基丙二酸和Fgf21水平降低、生存改善,且所有治疗小鼠及对照同窝仔中未观察到肝细胞癌。
  • 随时间推移,转基因表达增加、甲基丙二酸进行性降低,白蛋白-MMUT整合及校正肝细胞数量增加,而野生型动物无此现象。

核心结论

  • AAV介导的针对白蛋白基因座的无启动子无核酸酶基因组编辑,在新生期治疗的MMA小鼠中提供安全且持久的治疗获益。

研究设计与样本

  • 研究设计携带无启动子整合盒的AAV载体,将MMUT转基因插入白蛋白基因座3'端,并在MMA小鼠模型中测试。
  • 新生期递送后纵向评估肝脏转基因表达、血浆甲基丙二酸水平、MMA生物标志物Fgf21及白蛋白基因座MMUT整合。
  • 剖检时对所有治疗的MMA小鼠及对照同窝仔筛查AAV相关肝细胞癌。

主要发现

  • AAV介导的MMUT编辑入白蛋白基因座在MMA小鼠模型中实现永久肝脏校正,伴随甲基丙二酸和Fgf21水平降低及生存改善,且无肝细胞癌。
  • 随时间推移,转基因表达水平增加、甲基丙二酸进行性降低,MMA小鼠中白蛋白-MMUT整合数量及校正肝细胞数量增加,而类似治疗的野生型动物无此现象。
  • MMA背景下MMUT表达赋予编辑细胞选择性生长优势,增强治疗反应。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Adeno-associated viral (AAV) gene therapy has shown great promise as an alternative treatment for metabolic disorders managed using liver transplantation, but remains limited by transgene loss and genotoxicity. Our study aims to test an AAV vector with a promoterless integrating cassette, designed to provide sustained hepatic transgene expression and reduced toxicity in comparison to canonical AAV therapy. APPROACH AND RESULTS: Our AAV vector was designed to insert a methylmalonyl-CoA mutase (MMUT) transgene into the 3' end of the albumin locus and tested in mouse models of methylmalonic acidemia (MMA). After neonatal delivery, we longitudinally evaluated hepatic transgene expression, plasma levels of methylmalonate, and the MMA biomarker, fibroblast growth factor 21 (Fgf21), as well as integration of MMUT in the albumin locus. At necropsy, we surveyed for AAV-related hepatocellular carcinoma (HCC) in all treated MMA mice and control littermates. AAV-mediated genome editing of MMUT into the albumin locus resulted in permanent hepatic correction in MMA mouse models, which was accompanied by decreased levels of methylmalonate and Fgf21, and improved survival without HCC. With time, levels of transgene expression increased and methylmalonate progressively decreased, whereas the number of albumin-MMUT integrations and corrected hepatocytes in MMA mice increased, but not in similarly treated wild-type animals. Additionally, expression of MMUT in the setting of MMA conferred a selective growth advantage upon edited cells, which potentiates the therapeutic response. CONCLUSIONS: In conclusion, our findings demonstrate that AAV-mediated, promoterless, nuclease-free genome editing at the albumin locus provides safe and durable therapeutic benefit in neonatally treated MMA mice.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Chandler RJ, Venturoni LE, Liao J, et al. Promoterless, Nuclease-Free Genome Editing Confers a Growth Advantage for Corrected Hepatocytes in Mice With Methylmalonic Acidemia. Hepatology. 2021. PMID: 32976669. doi:10.1002/hep.31570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。